FINWIRES · TerminalLIVE
FINWIRES

調査速報:ASMLはメモリ需要の好調を背景に業績予想を上回り、株価も上昇。中国関連事業のエクスポージャーは大幅に減少。

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。ASMLは、2026年第1四半期の売上高が87億7000万ユーロ(前年同期比13%増)となり、市場予想の86億8000万ユーロを上回りました。1株当たり利益(EPS)は7.15ユーロ(前年同期比19%増)となり、市場予想の6.62ユーロを8%上回りました。売上総利益率は53.0%となり、ガイダンス(51%~53%)の上限に達しました。これは、高収益の既存顧客向け事業が予想を上回ったことによるもので、堅調なアップグレード需要(今後も継続すると見込まれる)が寄与したと考えられます。メモリは、システム純売上高の51%を占め(第4四半期は30%)、AI需要、メモリ不足の継続、EUVリソグラフィの普及拡大に支えられ、需要は引き続き堅調に推移しています。 2026年の売上高見通しは、不確実性は高まっているものの、EUV以外の事業見通しが改善したことにより、365億ユーロから約380億ユーロ(+16.3%)に引き上げられました。経営陣は、EUVの生産能力が2026年には60以上の低NAシステム(2025年は約50)に、2027年には80以上に拡大すると予想しており、これは2025年の業績を牽引した価格/スループットの進歩に加えて、大きな成長の原動力になると考えています。中国へのエクスポージャーは第1四半期の売上高の19%(第4四半期は36%)に大幅に低下した一方、韓国は45%(第22%)に急増し、メモリメーカーの需要加速を反映しています。

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.

$HIG
Research

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.

$BKR
Research

Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.

$WAB